Blue Jet Healthcare posts ₹782.64M Q1 profit, approves dividend
Blue Jet Healthcare posted a Q1FY27 net profit of ₹782.64 million, down 14.2% YoY, with revenue falling to ₹2,931.13 million. The Board approved a ₹1.2 interim dividend and reappointed Akshay B Arora and Shiven Akshay Arora for five-year terms.
*this image is generated using AI for illustrative purposes only.
Blue Jet Healthcare reported a net profit of ₹782.64 million for the first quarter ended June 30, 2026 (Q1FY27), driven by revenue from operations of ₹2,931.13 million. On August 3, 2026, the company’s Board of Directors approved the unaudited standalone financial results, declared an interim dividend of ₹1.2 per equity share, and secured shareholder approval for the reappointment of its Executive Chairman, Managing Director, and Statutory Auditors for five-year terms.
The financial performance reflects a year-on-year decline in both revenue and profitability compared to Q1FY26, where revenue stood at ₹3,547.58 million and net profit was ₹911.70 million. However, the company maintained robust margins, with EBITDA recorded at ₹980 million (derived from total income and expenses) and an EBITDA margin of approximately 33.5%. The dividend payout represents a 60% distribution relative to earnings, with September 14, 2026, set as the record date for determining entitlement.
Q1FY27 Financial Highlights
The following table outlines the key financial metrics for the quarter ended June 30, 2026, alongside comparative figures from the previous year:
| Metric | Q1FY27 (₹M) | Q1FY26 (₹M) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 2,931.13 | 3,547.58 | -17.4% |
| Other Income | 152.37 | 82.54 | +84.6% |
| Total Income | 3,083.50 | 3,630.12 | -15.1% |
| Total Expenses | 2,024.04 | 2,401.52 | -15.7% |
| Profit Before Tax | 1,059.46 | 1,228.60 | -13.8% |
| Net Profit After Tax | 782.64 | 911.70 | -14.2% |
Revenue from operations decreased by ₹616.45 million year-on-year. Despite this, cost management efforts resulted in a proportional reduction in total expenses, which fell by ₹377.48 million to ₹2,024.04 million. Other income increased significantly to ₹152.37 million from ₹82.54 million in the prior period, partially offsetting the decline in core operational revenue. Tax expense for the quarter was ₹276.82 million, comprising current tax of ₹265.00 million and deferred tax charge of ₹11.82 million.
Board Approvals and Corporate Actions
In addition to the financial results, the Board approved several key corporate governance actions subject to shareholder ratification at the ensuing Annual General Meeting (AGM) scheduled for September 21, 2026:
- Reappointment of Executive Chairman: Mr. Akshay B Arora was reappointed as Whole Time Director and Executive Chairman for a term of five years, effective April 13, 2027, to April 12, 2032. He is liable to retire by rotation.
- Reappointment of Managing Director: Mr. Shiven Akshay Arora was reappointed as Managing Director for a similar five-year term, effective April 13, 2027, to April 12, 2032. He is not liable to retire by rotation.
- Statutory Auditor Reappointment: M/s KKC & Associates LLP, Chartered Accountants, was reappointed as Statutory Auditors for a second consecutive term of five years, until the conclusion of the 63rd AGM in FY2030-31.
What the Numbers Show
The divergence between revenue decline (-17.4%) and expense reduction (-15.7%) indicates slight pressure on operating leverage in Q1FY27. While top-line growth contracted, the company’s ability to reduce costs nearly in line with revenue helped contain the net profit decline to 14.2%, which is less severe than the revenue drop. The significant rise in other income suggests non-operational gains contributed meaningfully to the bottom line, highlighting a dependency on non-core earnings to cushion operational headwinds. The approved dividend of ₹1.2 per share signals management’s confidence in cash flow stability despite the quarterly revenue dip.
Historical Stock Returns for Blue Jet Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.39% | +5.62% | +14.00% | +46.02% | -25.71% | +44.84% |
What specific operational factors or market conditions contributed to the 17.4% year-on-year decline in revenue from operations for Blue Jet Healthcare?
How sustainable is the company's reliance on a significant increase in other income to offset the contraction in core operational revenue?
Will the reappointment of the Executive Chairman and Managing Director for five-year terms signal a shift in strategic focus to reverse the recent top-line growth slowdown?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
